Sopharma AD-SofiaWAR:SPH -0.25%67 Altman Z2-Score is 3.25 as of Jun. 30, 2026, which is 0% above its 10-year median of 3.24. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł12.97 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, Sopharma AD-Sofia ranks better than 64.1% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Sopharma AD-Sofia has a Altman Z2-Score of 3.25, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Sopharma AD-Sofia's Altman Z2-Score or its related term are showing as below:
WAR:SPH'
s Altman Z2-Score Range Over the Past 10 Years
Min: 2.17 Med: 3.24 Max: 4.39
Current: 3.24
During the past 13 years, Sopharma AD-Sofia's highest Altman Z2-Score was 4.39. The lowest was 2.17. And the median was 3.24.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Sopharma AD-Sofia Altman Z2-Score Related Terms
Sopharma AD-Sofia Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:SPH vs MCK, CAH, COR: Altman Z2-Score Comparison
For the Medical Distribution subindustry, Sopharma AD-Sofia's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Altman Z2-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Sopharma AD-Sofia's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.1444
+
3.26
*
0.1945
+
6.72
*
0.0949
+
1.05
*
0.9805
=
3.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Sopharma AD-Sofia (WAR:SPH) has a Altman Z2-Score of 3.25 as of Jun. 30, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sopharma AD-Sofia and its competitors. This is near median its historical median of 3.24. Over the past decade, Sopharma AD-Sofia's Altman Z2-Score has ranged from 2.17 to 4.39. According to the industry distribution chart, Sopharma AD-Sofia ranks #42 out of 117 companies in the Medical Distribution industry, placing it in the top 35.9%.
Is Sopharma AD-Sofia's Altman Z2-Score too high?
Sopharma AD-Sofia's current Altman Z2-Score of 3.25 is near median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 2.17 to a high of 4.39. The Medical Distribution industry median Altman Z2-Score is 2.77. Sopharma AD-Sofia's value of 3.25 is 17.3% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #42 out of 117 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Altman Z2-Score compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #42 out of 117 companies for Altman Z2-Score. This puts Sopharma AD-Sofia in the upper half of its industry. The industry median Altman Z2-Score is 2.77. Sopharma AD-Sofia's value of 3.25 is 17.3% above this benchmark. Historically, Sopharma AD-Sofia's own Altman Z2-Score has ranged from 2.17 to 4.39 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 2.77, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Distribution company?
The median Altman Z2-Score among Medical Distribution companies is 2.77, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Altman Z2-Score of 3.25 is 17.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Altman Z2-Score is 2.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Altman Z2-Score is 3.25, which is near median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł12.97, compared to a current price of zł7.90 — trading 39.1% below its estimated fair value. The current Altman Z2-Score is 3.25, which is near median its 10-year median of 3.24 and 17.3% above the Medical Distribution industry median of 2.77. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Altman Z2-Score is 3.25 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.90 is trading 39.1% below its estimated GF Value™ of zł12.97.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Altman Z2-Score: 3.25 (near median its 10-year median of 3.24)
GF Value™: zł12.97 vs. price of zł7.90 (39.1% below fair value)
Industry Position: 17.3% above the Medical Distribution median (#42 of 117)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
